

# Donald W Kufe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/355967/publications.pdf>

Version: 2024-02-01

218  
papers

16,823  
citations

16791

66  
h-index

18400

124  
g-index

221  
all docs

221  
docs citations

221  
times ranked

13589  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas. <i>Carcinogenesis</i> , 2022, 43, 67-76.  | 1.3 | 10        |
| 2  | Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer. <i>Theranostics</i> , 2022, 12, 999-1011.                                      | 4.6 | 5         |
| 3  | MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2022, 20, 556-567.   | 1.5 | 17        |
| 4  | MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. <i>Oncolmmunology</i> , 2022, 11, 2029298.   | 2.1 | 17        |
| 5  | Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells. <i>Journal of Cancer Metastasis and Treatment</i> , 2022, 8, .   | 0.5 | 9         |
| 6  | Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2580.  | 1.7 | 14        |
| 7  | Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non- $\mu$ neuroendocrine Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1379-1390.  | 1.5 | 8         |
| 8  | Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. <i>Oncogene</i> , 2022, 41, 3511-3523.   | 2.6 | 10        |
| 9  | MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. <i>Cancer Research</i> , 2021, 81, 1111-1122.   | 0.4 | 46        |
| 10 | MUC1-C integrates activation of the IFN- $\gamma$ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. , 2021, 9, e002115.  |     | 41        |
| 11 | Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. <i>Haematologica</i> , 2021, 106, 1330-1342.                              | 1.7 | 19        |
| 12 | MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. <i>Oncogene</i> , 2021, 40, 4930-4940.                                     | 2.6 | 41        |
| 13 | The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. <i>Frontiers in Immunology</i> , 2021, 12, 735609. | 2.2 | 10        |
| 14 | Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 904-904.   | 0.6 | 0         |
| 15 | Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. <i>Blood</i> , 2021, 138, 2830-2830.   | 0.6 | 1         |
| 16 | Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances. <i>Blood</i> , 2021, 138, 737-737.  | 0.6 | 0         |
| 17 | MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. <i>Carcinogenesis</i> , 2020, 41, 1173-1183.  | 1.3 | 49        |
| 18 | Role of the MUC1- $\mu$ oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. <i>Cancer Science</i> , 2020, 111, 3639-3652.  | 1.7 | 22        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.              |     | 7         |
| 20 | Anti-MUC1-C Antibody- $\alpha$ Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1380-1389.                 | 0.4 | 14        |
| 21 | MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nature Communications, 2020, 11, 338.  | 5.8 | 87        |
| 22 | MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight, 2020, 5, .  | 2.3 | 36        |
| 23 | Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. Blood, 2020, 136, 10-10.   | 0.6 | 0         |
| 24 | MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. Oncogene, 2019, 38, 7266-7277.  | 2.6 | 17        |
| 25 | Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 1744-1754.  | 1.9 | 49        |
| 26 | MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. Cancer Research, 2019, 79, 5711-5722.  | 0.4 | 45        |
| 27 | Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. British Journal of Haematology, 2019, 185, 679-690.        | 1.2 | 52        |
| 28 | MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells. Cancer Research, 2019, 79, 2031-2041.  | 0.4 | 28        |
| 29 | CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. Blood, 2019, 134, 1386-1386.  | 0.6 | 2         |
| 30 | Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. Blood, 2019, 134, 392-392.  | 0.6 | 2         |
| 31 | T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. Blood, 2019, 134, 2673-2673.   | 0.6 | 2         |
| 32 | Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. Blood, 2019, 134, 3832-3832.   | 0.6 | 0         |
| 33 | Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. Blood, 2019, 134, 3227-3227. | 0.6 | 1         |
| 34 | MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. Oncogene, 2018, 37, 2079-2088.   | 2.6 | 50        |
| 35 | MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. Cancer Research, 2018, 78, 205-215.   | 0.4 | 167       |
| 36 | MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. Journal of Cellular and Molecular Medicine, 2018, 22, 3887-3898.  | 1.6 | 12        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 13.  | 7.1 | 36        |
| 38 | Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. <i>JCI Insight</i> , 2018, 3, .  | 2.3 | 52        |
| 39 | Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy. <i>Blood</i> , 2018, 132, 2728-2728. | 0.6 | 1         |
| 40 | A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. <i>Blood</i> , 2018, 132, 1446-1446.   | 0.6 | 2         |
| 41 | MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1791-1801.  | 0.6 | 130       |
| 42 | Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <sc>MUC</sc>1. <i>British Journal of Haematology</i> , 2017, 176, 929-938.  | 1.2 | 34        |
| 43 | Targeting MUC1-C inhibits the AKT-S6K1-eIF4A pathway regulating TIGAR translation in colorectal cancer. <i>Molecular Cancer</i> , 2017, 16, 33.  | 7.9 | 48        |
| 44 | Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1833-1839.  | 1.7 | 13        |
| 45 | MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 117-122.  | 3.3 | 62        |
| 46 | MUC1-C activates EZH2 expression and function in human cancer cells. <i>Scientific Reports</i> , 2017, 7, 7481.  | 1.6 | 38        |
| 47 | Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2304-2314.  | 1.9 | 10        |
| 48 | MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1338998.  | 2.1 | 44        |
| 49 | <sc>MUC</sc>1 is a target in lenalidomide resistant multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 914-926.  | 1.2 | 20        |
| 50 | CBP501 suppresses macrophage induced cancer stem cell like features and metastases. <i>Oncotarget</i> , 2017, 8, 64015-64031.  | 0.8 | 5         |
| 51 | Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 69237-69249.   | 0.8 | 8         |
| 52 | CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice. <i>Oncotarget</i> , 2017, 8, 78277-78288.   | 0.8 | 14        |
| 53 | Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. <i>Oncotarget</i> , 2016, 7, 11756-11769.  | 0.8 | 144       |
| 54 | MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. <i>Scientific Reports</i> , 2016, 6, 26643.   | 1.6 | 36        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. <i>Science Translational Medicine</i> , 2016, 8, 368ra171. | 5.8 | 140       |
| 56 | MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. <i>Molecular Cancer Research</i> , 2016, 14, 1266-1276.  | 1.5 | 36        |
| 57 | MUC1-C drives MYC in multiple myeloma. <i>Blood</i> , 2016, 127, 2587-2597.  | 0.6 | 71        |
| 58 | MUC1 in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2489-2498.  | 0.6 | 22        |
| 59 | Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. <i>Cancer Research</i> , 2016, 76, 1538-1548.                                  | 0.4 | 84        |
| 60 | MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 38974-38987.   | 0.8 | 36        |
| 61 | Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4175-4175.   | 0.6 | 0         |
| 62 | MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. <i>Blood</i> , 2016, 128, 2871-2871.  | 0.6 | 1         |
| 63 | MUC1-C drives DNA methylation in cancer. <i>Aging</i> , 2016, 8, 3155-3156.  | 1.4 | 1         |
| 64 | Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. <i>Blood</i> , 2016, 128, 703-703.             | 0.6 | 0         |
| 65 | Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood</i> , 2015, 126, 354-362.   | 0.6 | 31        |
| 66 | Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. <i>PLoS ONE</i> , 2015, 10, e0135156.  | 1.1 | 47        |
| 67 | Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. <i>Clinical Cancer Research</i> , 2015, 21, 2338-2347.                                       | 3.2 | 51        |
| 68 | MUC1-C Induces the LIN28B-LET-7-HMGA2 Axis to Regulate Self-Renewal in NSCLC. <i>Molecular Cancer Research</i> , 2015, 13, 449-460.  | 1.5 | 53        |
| 69 | MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2473-2473.  | 0.6 | 2         |
| 70 | MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells. <i>Blood</i> , 2015, 126, 643-643.                | 0.6 | 0         |
| 71 | Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3659-3659.  | 0.6 | 0         |
| 72 | Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2215-2225.                                 | 1.9 | 10        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non-Small Cell Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2014, 20, 5423-5434.                                 | 3.2 | 60        |
| 74 | Novel Polymeric Nanoparticles for Intracellular Delivery of Peptide Cargos: Antitumor Efficacy of the BCL-2 Conversion Peptide NuBCP-9. <i>Cancer Research</i> , 2014, 74, 3271-3281.                                   | 0.4 | 56        |
| 75 | MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. <i>Blood</i> , 2014, 123, 734-742.  | 0.6 | 16        |
| 76 | Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. <i>Blood</i> , 2014, 123, 2997-3006.  | 0.6 | 58        |
| 77 | Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression. <i>Blood</i> , 2014, 124, 2072-2072.               | 0.6 | 3         |
| 78 | Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. <i>Oncotarget</i> , 2014, 5, 2622-2634.   | 0.8 | 59        |
| 79 | MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. <i>Oncotarget</i> , 2014, 5, 8893-8905.  | 0.8 | 54        |
| 80 | MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 808-808.   | 0.6 | 0         |
| 81 | Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 2303-2303.   | 0.6 | 0         |
| 82 | Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression. <i>Blood</i> , 2014, 124, 226-226.   | 0.6 | 0         |
| 83 | Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1. <i>Blood</i> , 2014, 124, 3378-3378.   | 0.6 | 0         |
| 84 | Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. <i>Clinical Cancer Research</i> , 2013, 19, 3640-3648. | 3.2 | 199       |
| 85 | MUC1-C Oncoprotein Activates ERK1/2 Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 30892-30903.                                      | 1.6 | 72        |
| 86 | Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 714-723.  | 1.5 | 52        |
| 87 | MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. <i>Cancer Research</i> , 2013, 73, 5569-5579.  | 0.4 | 49        |
| 88 | Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. <i>Cancer Biology and Therapy</i> , 2013, 14, 127-134.   | 1.5 | 37        |
| 89 | Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. <i>Blood</i> , 2013, 122, 3928-3928.  | 0.6 | 7         |
| 90 | STAT3 Inhibition Promotes Potent Th1 Responses By Down Regulating Pdl-1 Expression On Tumor Cells. <i>Blood</i> , 2013, 122, 3217-3217.   | 0.6 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. <i>Blood</i> , 2013, 122, 127-127.                  | 0.6 | 0         |
| 92  | Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. <i>International Journal of Oncology</i> , 2012, 40, 1643-9.   | 1.4 | 57        |
| 93  | The MUC1-C Oncoprotein Binds to the BH3 Domain of the Pro-apoptotic BAX Protein and Blocks BAX Function. <i>Journal of Biological Chemistry</i> , 2012, 287, 20866-20875.                          | 1.6 | 46        |
| 94  | MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 10703-10713. | 1.6 | 63        |
| 95  | Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. <i>Blood</i> , 2012, 119, 810-816.                               | 0.6 | 93        |
| 96  | MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. <i>Prostate</i> , 2012, 72, 1659-1668.  | 1.2 | 46        |
| 97  | Cooperative Interaction between the MUC1-C Oncoprotein and the Rab31 GTPase in Estrogen Receptor-Positive Breast Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e39432.                                  | 1.1 | 39        |
| 98  | Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. <i>Prostate</i> , 2011, 71, 1299-1308.  | 1.2 | 33        |
| 99  | A Monoclonal Antibody Against the Oncogenic Mucin 1 Cytoplasmic Domain. <i>Hybridoma</i> , 2011, 30, 531-535.  | 0.5 | 20        |
| 100 | Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 806-816.  | 1.9 | 144       |
| 101 | MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop. <i>Science Signaling</i> , 2011, 4, ra9.   | 1.6 | 84        |
| 102 | MUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated Mechanism. <i>Genes and Cancer</i> , 2011, 2, 56-64.                                    | 0.6 | 19        |
| 103 | Mucin 1 C-Terminal Subunit Oncoprotein Is a Target for Small-Molecule Inhibitors. <i>Molecular Pharmacology</i> , 2011, 79, 886-893.   | 1.0 | 44        |
| 104 | MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. <i>Blood</i> , 2011, 117, 4863-4870.                                   | 0.6 | 33        |
| 105 | MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e28234.  | 1.1 | 53        |
| 106 | Mucin 1 Oncoprotein Expression Is Suppressed by the miR-125b Oncomir. <i>Genes and Cancer</i> , 2010, 1, 62-68.  | 0.6 | 69        |
| 107 | MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation. <i>Genes and Cancer</i> , 2010, 1, 239-250.   | 0.6 | 22        |
| 108 | miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. <i>International Journal of Oncology</i> , 2010, 37, 61-9.  | 1.4 | 39        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. <i>BMC Medical Genomics</i> , 2010, 3, 16.  | 0.7  | 55        |
| 110 | Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function. <i>Molecular Pharmacology</i> , 2010, 78, 166-174.  | 1.0  | 31        |
| 111 | Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. <i>Cancer Biology and Therapy</i> , 2010, 10, 483-491.   | 1.5  | 21        |
| 112 | Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. <i>Blood</i> , 2010, 116, 848-848.   | 0.6  | 1         |
| 113 | MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor- $\kappa$ B p65 Transcription Factor. <i>Cancer Research</i> , 2009, 69, 7013-7021.   | 0.4  | 164       |
| 114 | Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells. <i>Cancer Research</i> , 2009, 69, 5133-5141.  | 0.4  | 132       |
| 115 | MUC1 oncoprotein is a druggable target in human prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3056-3065.  | 1.9  | 68        |
| 116 | Functional targeting of the MUC1 oncogene in human cancers. <i>Cancer Biology and Therapy</i> , 2009, 8, 1197-1203.  | 1.5  | 99        |
| 117 | MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5837-5841. | 3.3  | 106       |
| 118 | Mucins in cancer: function, prognosis and therapy. <i>Nature Reviews Cancer</i> , 2009, 9, 874-885.  | 12.8 | 1,148     |
| 119 | MUC1-Induced Transcriptional Programs Associated with Tumorigenesis Predict Outcome in Breast and Lung Cancer. <i>Cancer Research</i> , 2009, 69, 2833-2837.   | 0.4  | 98        |
| 120 | MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. <i>International Journal of Oncology</i> , 2009, 34, 1691-9.  | 1.4  | 41        |
| 121 | Targeting the human MUC1 oncoprotein: A tale of two proteins. <i>Cancer Biology and Therapy</i> , 2008, 7, 81-84.  | 1.5  | 40        |
| 122 | Muc1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. <i>Cancer Biology and Therapy</i> , 2008, 7, 1959-1967.  | 1.5  | 24        |
| 123 | Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)â€™Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3. <i>Cancer Research</i> , 2008, 68, 2920-2926.     | 0.4  | 107       |
| 124 | MUC1 Oncoprotein Blocks Death Receptorâ€™Mediated Apoptosis by Inhibiting Recruitment of Caspase-8. <i>Cancer Research</i> , 2008, 68, 6136-6144.  | 0.4  | 79        |
| 125 | MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. <i>International Journal of Oncology</i> , 2008, 33, 153-9.   | 1.4  | 23        |
| 126 | Mucin 1 Oncoprotein Blocks Hypoxia-inducible Factor 1 $\beta$ Activation in a Survival Response to Hypoxia. <i>Journal of Biological Chemistry</i> , 2007, 282, 257-266.   | 1.6  | 64        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells. <i>Cancer Research</i> , 2007, 67, 11576-11584.                                    | 0.4 | 41        |
| 128 | Nuclear Import of the MUC1-C Oncoprotein Is Mediated by Nucleoporin Nup62. <i>Journal of Biological Chemistry</i> , 2007, 282, 19321-19330.   | 1.6 | 120       |
| 129 | Human Mucin 1 Oncoprotein Represses Transcription of the p53 Tumor Suppressor Gene. <i>Cancer Research</i> , 2007, 67, 1853-1858.   | 0.4 | 89        |
| 130 | Evolution of the human MUC1 oncoprotein. <i>International Journal of Oncology</i> , 2007, 31, 671.  | 1.4 | 14        |
| 131 | The MUC1 and Galectin-3 Oncoproteins Function in a MicroRNA-Dependent Regulatory Loop. <i>Molecular Cell</i> , 2007, 27, 992-1004.  | 4.5 | 165       |
| 132 | MUC1 oncoprotein activates the I $\kappa$ B kinase I $\kappa$ 2 complex and constitutive NF- $\kappa$ B signalling. <i>Nature Cell Biology</i> , 2007, 9, 1419-1427.                    | 4.6 | 174       |
| 133 | Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007, 110, 284-284.   | 0.6 | 2         |
| 134 | Evolution of the human MUC1 oncoprotein. <i>International Journal of Oncology</i> , 2007, 31, 671-7.  | 1.4 | 16        |
| 135 | Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. <i>Gene</i> , 2006, 373, 28-34.  | 1.0 | 95        |
| 136 | MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor I $\alpha$ . <i>Molecular Cell</i> , 2006, 21, 295-305.   | 4.5 | 174       |
| 137 | MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. <i>EMBO Journal</i> , 2006, 25, 3774-3783.  | 3.5 | 84        |
| 138 | A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 329-335.             | 1.1 | 44        |
| 139 | MUC1 Oncoprotein Functions in Activation of Fibroblast Growth Factor Receptor Signaling. <i>Molecular Cancer Research</i> , 2006, 4, 873-883.   | 1.5 | 80        |
| 140 | Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3080-3080.        | 0.6 | 0         |
| 141 | Stimulation of Anti-Tumor Immunity Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28.. <i>Blood</i> , 2006, 108, 3715-3715.  | 0.6 | 0         |
| 142 | Stimulation of Anti-Tumor Immunity Using Dendritic Cells Transduced with Fowl Pox Vector Expressing MUC-1 and Costimulatory Molecules (PANVAC-F).. <i>Blood</i> , 2006, 108, 5209-5209. | 0.6 | 0         |
| 143 | Chemoinducible gene therapy. <i>Anti-Cancer Drugs</i> , 2005, 16, 1053-1058.  | 0.7 | 5         |
| 144 | Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. <i>Cancer Cell</i> , 2005, 7, 167-178.   | 7.7 | 222       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 610-614.   | 1.1 | 5         |
| 146 | Dendritic Cells Induce MUC1 Expression and Polarization on Human T Cells by an IL-7-Dependent Mechanism. <i>Journal of Immunology</i> , 2005, 174, 2376-2386.  | 0.4 | 30        |
| 147 | c-Abl Tyrosine Kinase Regulates Caspase-9 Autocleavage in the Apoptotic Response to DNA Damage. <i>Journal of Biological Chemistry</i> , 2005, 280, 11147-11151.   | 1.6 | 54        |
| 148 | Dendritic cell fusion vaccines for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 703-715.   | 1.4 | 41        |
| 149 | MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3 $\beta$ -Mediated Phosphorylation and Degradation of $\beta$ -Catenin. <i>Cancer Research</i> , 2005, 65, 10413-10422.  | 0.4 | 206       |
| 150 | Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML. <i>Blood</i> , 2005, 106, 2788-2788.   | 0.6 | 0         |
| 151 | 2-(8-Hydroxy-6-methoxy-1-oxo-1 $\beta$ -2-benzopyran-3-yl)propionic Acid, a Small Molecule Isocoumarin, Potentiates Dexamethasone-Induced Apoptosis of Human Multiple Myeloma Cells. <i>Cancer Research</i> , 2004, 64, 8512-8516. | 0.4 | 32        |
| 152 | The MUC1 Oncoprotein Activates the Anti-apoptotic Phosphoinositide 3-Kinase/Akt and Bcl-xL Pathways in Rat 3Y1 Fibroblasts. <i>Journal of Biological Chemistry</i> , 2004, 279, 20607-20612.                                       | 1.6 | 149       |
| 153 | MUC1 Oncoprotein Activates the FOXO3a Transcription Factor in a Survival Response to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2004, 279, 45721-45727.  | 1.6 | 97        |
| 154 | Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. <i>Cancer Cell</i> , 2004, 5, 163-175.  | 7.7 | 309       |
| 155 | Interaction of human MUC1 and $\beta$ -catenin is regulated by Lck and ZAP-70 in activated Jurkat T cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 471-476.  | 1.0 | 39        |
| 156 | Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial. <i>Blood</i> , 2004, 104, 751-751.   | 0.6 | 3         |
| 157 | Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. <i>Oncogene</i> , 2003, 22, 6107-6110.   | 2.6 | 191       |
| 158 | Human MUC1 Carcinoma Antigen Regulates Intracellular Oxidant Levels and the Apoptotic Response to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2003, 278, 35458-35464.   | 1.6 | 148       |
| 159 | Radiation Therapy $\rightarrow$ Activation of Gene Transcription and the Development of Genetic Radiotherapy: Therapeutic Strategies in Oncology. <i>Cancer Biology and Therapy</i> , 2003, 2, 326-329.                            | 1.5 | 58        |
| 160 | DF3/MUC1 Signaling In Multiple Myeloma Cells Is Regulated by Interleukin-7. <i>Cancer Biology and Therapy</i> , 2003, 2, 187-193.  | 1.5 | 72        |
| 161 | Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. <i>Molecular Cancer Research</i> , 2003, 1, 765-75.   | 1.5 | 81        |
| 162 | MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. <i>Cancer Biology and Therapy</i> , 2003, 2, 702-6.  | 1.5 | 53        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 163 | Protein Kinase C $\zeta$ Regulates Function of the DF3/MUC1 Carcinoma Antigen in $\beta$ -Catenin Signaling. <i>Journal of Biological Chemistry</i> , 2002, 277, 17616-17622.  | 1.6  | 131       |
| 164 | Inhibition of c-Abl with STI571 Attenuates Stress-Activated Protein Kinase Activation and Apoptosis in the Cellular Response to 1- $\beta$ -d-Arabinofuranosylcytosine. <i>Molecular Pharmacology</i> , 2002, 61, 1489-1495. | 1.0  | 17        |
| 165 | Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. <i>Cancer Research</i> , 2002, 62, 789-95.  | 0.4  | 37        |
| 166 | Targeting of the c-Abl Tyrosine Kinase to Mitochondria in Endoplasmic Reticulum Stress-Induced Apoptosis. <i>Molecular and Cellular Biology</i> , 2001, 21, 6233-6242.   | 1.1  | 121       |
| 167 | Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 347-355.  | 1.1  | 14        |
| 168 | Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. <i>Journal of Gastroenterology</i> , 2001, 36, 764-771.                  | 2.3  | 68        |
| 169 | The Epidermal Growth Factor Receptor Regulates Interaction of the Human DF3/MUC1 Carcinoma Antigen with c-Src and $\beta$ -Catenin. <i>Journal of Biological Chemistry</i> , 2001, 276, 35239-35242.                         | 1.6  | 229       |
| 170 | The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated Antigen with GSK3 $\beta$ and $\beta$ -Catenin. <i>Journal of Biological Chemistry</i> , 2001, 276, 6061-6064.                      | 1.6  | 203       |
| 171 | Targeting of the c-Abl Tyrosine Kinase to Mitochondria in the Necrotic Cell Death Response to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2001, 276, 17281-17285.   | 1.6  | 93        |
| 172 | Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells. <i>Oncogene</i> , 2000, 19, 3941-3947.  | 2.6  | 41        |
| 173 | Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. <i>Oncogene</i> , 2000, 19, 1975-1981.   | 2.6  | 284       |
| 174 | A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 319-328.                  | 1.1  | 28        |
| 175 | Activation of the Cytoplasmic c-Abl Tyrosine Kinase by Reactive Oxygen Species. <i>Journal of Biological Chemistry</i> , 2000, 275, 17237-17240.   | 1.6  | 138       |
| 176 | Activation of MEK Kinase 1 by the c-Abl Protein Tyrosine Kinase in Response to DNA Damage. <i>Molecular and Cellular Biology</i> , 2000, 20, 4979-4989.  | 1.1  | 90        |
| 177 | Role for Lyn Tyrosine Kinase as a Regulator of Stress-Activated Protein Kinase Activity in Response to DNA Damage. <i>Molecular and Cellular Biology</i> , 2000, 20, 5370-5380.  | 1.1  | 60        |
| 178 | Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-xL in Response to DNA Damage. <i>Journal of Biological Chemistry</i> , 2000, 275, 322-327.  | 1.6  | 384       |
| 179 | p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. <i>Nature</i> , 1999, 399, 814-817.   | 13.7 | 551       |
| 180 | Function for p300 and not CBP in the apoptotic response to DNA damage. <i>Oncogene</i> , 1999, 18, 5714-5717.  | 2.6  | 54        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 181 | Strategies for enhancing viral-based gene therapy using ionizing radiation. <i>Radiation Oncology Investigations</i> , 1999, 7, 261-269.  | 1.3  | 17        |
| 182 | Activation of protein kinase C $\beta$ by the c-Abl tyrosine kinase in response to ionizing radiation. <i>Oncogene</i> , 1998, 16, 1643-1648.   | 2.6  | 143       |
| 183 | Functional role for the c-Abl tyrosine kinase in meiosis. <i>Oncogene</i> , 1998, 16, 1773-1777.  | 2.6  | 45        |
| 184 | Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. <i>Oncogene</i> , 1998, 17, 1889-1892.   | 2.6  | 27        |
| 185 | Determination of cell fate by c-Abl activation in the response to DNA damage. <i>Oncogene</i> , 1998, 17, 3309-3318.  | 2.6  | 160       |
| 186 | Transgene Expression in Malignant Glioma Using a Replication-Defective Adenoviral Vector Containing the Egr-1 Promoter: Activation by Ionizing Radiation or Uptake of Radioactive Iododeoxyuridine. <i>Human Gene Therapy</i> , 1998, 9, 1409-1417. | 1.4  | 74        |
| 187 | Interaction of Glycogen Synthase Kinase $\beta$ with the DF3/MUC1 Carcinoma-Associated Antigen and $\beta$ -Catenin. <i>Molecular and Cellular Biology</i> , 1998, 18, 7216-7224.   | 1.1  | 236       |
| 188 | Adenovirus Vector-Based Purging of Multiple Myeloma Cells. <i>Blood</i> , 1998, 92, 4591-4601.  | 0.6  | 61        |
| 189 | Interaction of the DF3/MUC1 Breast Carcinoma-associated Antigen and $\beta$ -Catenin in Cell Adhesion. <i>Journal of Biological Chemistry</i> , 1997, 272, 12492-12494.   | 1.6  | 278       |
| 190 | Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1- $\beta$ -D-arabinofuranosylcytosine. <i>Oncogene</i> , 1997, 15, 1947-1952.  | 2.6  | 42        |
| 191 | Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. <i>Nature Medicine</i> , 1997, 3, 437-442.  | 15.2 | 195       |
| 192 | Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. <i>Nature Medicine</i> , 1997, 3, 558-561.   | 15.2 | 575       |
| 193 | Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. <i>Nature Medicine</i> , 1997, 3, 1145-1149.  | 15.2 | 158       |
| 194 | Functional interaction between DNA-PK and c-Abl in response to DNA damage. <i>Nature</i> , 1997, 386, 732-735.  | 13.7 | 259       |
| 195 | Genotoxic Drugs Induce Interaction of the c-Abl Tyrosine Kinase and the Tumor Suppressor Protein p53. <i>Journal of Biological Chemistry</i> , 1996, 271, 26457-26460.  | 1.6  | 64        |
| 196 | Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. <i>Nature Medicine</i> , 1996, 2, 567-573.  | 15.2 | 103       |
| 197 | Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. <i>Nature Medicine</i> , 1996, 2, 1367-1370.  | 15.2 | 164       |
| 198 | Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. <i>Nature</i> , 1996, 382, 272-274.   | 13.7 | 232       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 199 | Spatial and temporal control of gene therapy using ionizing radiation. <i>Nature Medicine</i> , 1995, 1, 786-791.   | 15.2 | 303       |
| 200 | Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents. <i>Nature</i> , 1995, 376, 785-788.  | 13.7 | 496       |
| 201 | 1-beta.-D-Arabinofuranosylcytosine Activates Tyrosine Phosphorylation of p34cdc2 and Its Association with the SRC-like p56/p53lyn Kinase in Human Myeloid Leukemia Cells. <i>Biochemistry</i> , 1995, 34, 1058-1063.  | 1.2  | 30        |
| 202 | c-Abl Activation Regulates Induction of the SEK1/Stress-activated Protein Kinase Pathway in the Cellular Response to 1-β-D-Arabinofuranosylcytosine. <i>Journal of Biological Chemistry</i> , 1995, 270, 30278-30281. | 1.6  | 108       |
| 203 | Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 227-235.                           | 2.0  | 6         |
| 204 | Stress response genes induced in mammalian cells by ionizing radiation. <i>Radiation Oncology Investigations</i> , 1993, 1, 81-93.  | 1.3  | 18        |
| 205 | Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. <i>Biochemistry</i> , 1992, 31, 8300-8306.   | 1.2  | 166       |
| 206 | Regulation of c-jun gene expression in HL-60 leukemia cells by 1-beta.-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism. <i>Biochemistry</i> , 1991, 30, 7947-7952.        | 1.2  | 48        |
| 207 | Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells. <i>FEBS Letters</i> , 1991, 294, 73-76.   | 1.3  | 13        |
| 208 | Inhibition of phorbol ester-induced monocytic differentiation by dexamethasone is associated with down-regulation of c-fos and c-jun (AP-1). <i>Journal of Cellular Physiology</i> , 1991, 149, 125-131.              | 2.0  | 29        |
| 209 | Effects of dexamethasone on induction of monocytic differentiation in human U-937 cells by dimethylsulfoxide. <i>Journal of Cellular Physiology</i> , 1990, 142, 261-267.   | 2.0  | 24        |
| 210 | Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. <i>Journal of Cellular Physiology</i> , 1990, 143, 226-231.  | 2.0  | 28        |
| 211 | Circulating Tumor Markers in Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1989, 3, 653-674.   | 0.9  | 27        |
| 212 | Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study. <i>Journal of the National Cancer Institute</i> , 1988, 80, 1039-1044.                     | 3.0  | 301       |
| 213 | Expression of the c-fms proto-oncogene during human monocytic differentiation. <i>Nature</i> , 1985, 316, 64-66.  | 13.7 | 278       |
| 214 | Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors. <i>Hybridoma</i> , 1984, 3, 223-232.   | 0.9  | 502       |
| 215 | Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin. <i>Cancer Chemotherapy and Pharmacology</i> , 1983, 10, 125-128.  | 1.1  | 14        |
| 216 | A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 301-4.  | 1.1  | 6         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Deoxycoformycin: Neurological toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 1981, 5, 193-196.                                      | 1.1 | 46        |
| 218 | Diverse TNF $\alpha$ -induced death pathways are enhanced by inhibition of NF- $\kappa$ B. <i>International Journal of Oncology</i> , 0, , . | 1.4 | 1         |